Axogen reports preliminary Q4 revenue $59.9M (+21.3% YoY); full-year $225.2M (+20.2%); FDA BLA approval for Avance

Axogen, Inc.

2025-FY EPS reported -$0.34 revenue$225,208,000

Q4 2025 revenue ~$59.9M (+21.3% YoY); full-year 2025 revenue ~$225.2M (+20.2% YoY).
Gross margin expected above 74% for Q4 and FY 2025; includes ~$1.9M one-time costs related to Avance BLA approval, 67% non-cash.
Cash, equivalents, restricted cash, and investments ~$45.5M at Dec 31, 2025, up ~$6.0M from end of 2024.
FDA approved Biologics License Application for Avance (acellular nerve allograft) on Dec 3, 2025.
Growth driven by commercial strategy targeting Extremities and OMF-Head & Neck, and increased Resensation penetration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.